BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for ...
BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
46 th Annual TD Cowen Healthcare Conference: Interested parties may access live and archived webcasts of the presentations on the “investors” section of the Company’s website at: ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024Achieved preliminary GAAP net income of $4.5 million, or $0.27 per shareReported preliminary Q1 ...
BioStem Technologies Inc. Annual cash flow by MarketWatch. View BSEM net cash flow, operating cash flow, operating expenses and cash dividends.
Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to NasdaqPOMPANO BEACH, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results